

## Guide to the 2021-2022 Subject Index

**Committee mandate:** The Select Special Committee to Examine Safe Supply was established by the Legislative Assembly through the passage of Government Motion 115 on December 7, 2021. The committee must report to the Legislative Assembly with recommendations by April 30, 2022.

The committee’s mandate is limited to consideration of:

- a. examining the concept of “safe supply,” defined as the provision of pharmaceutical opioids, heroin, crystal methamphetamine, cocaine, or other substances to people who are addicted to or dependent on these substances;
- b. whether there is evidence that a proposed “safe supply” would have an impact on fatal or non-fatal overdose, drug diversion, or associated health and community impacts;
- c. whether there is evidence that a proposed “safe supply” would be accompanied by increased risks to individuals, the community, other entities or jurisdictions
- d. examining historical evidence regarding the over-prescribing of opioids; and
- e. whether there is evidence that a proposed “safe supply” would be accompanied by any other benefits or consequences.

There are two indexes for the transcripts of meetings of the Standing Committee on Alberta’s Economic Future, a **subject index** and a **speaker index**. Interim indexes are unedited and are not considered official. Committee activities during the 30th Legislature, Second Session (February 25, 2020 – February 21, 2022) are as follows.

### Abbreviations

#### *Political parties*

Ind.	Independent (no party affiliation)
NDP	New Democratic Party
UCP	United Conservative Party

Abbreviations not included in the above list are in the subject index in alphabetical order.

### Committee meeting dates and page ranges with links to transcripts:

<i>Committee meeting dates</i>	<i>Pages</i>
January 18, 2022 .....	<a href="#">ESS1-10</a>
February 3, 2022 .....	<a href="#">ESS11-28</a>
February 15, 2022 (stakeholder presentations).....	<a href="#">ESS29-60</a>
February 16, 2022 (stakeholder presentations).....	<a href="#">ESS61-96</a>
February 17, 2022 (stakeholder presentations) .....	<a href="#">ESS97-116</a>



**Aboriginal relations**

Treaty acknowledgment ... *Somers* ESS29

**Addiction**

Definition of recovery ... *Somers* ESS30

Definition of rehabilitation ... *Rosin* ESS33; *Somers* ESS30-31, 33

General remarks ... *Stephan* ESS87; *Thiessen* ESS87

Professional addicts (physicians, etc.) ... *Somers* ESS31

Recovery ... *Melamed* ESS82; *Milliken* ESS81-82

Recovery, statistics ... *Amery* ESS68; *Devine* ESS68

Scientific research *See* **Stanford-Lancet Commission on the North American Opioid Crisis**

**Addiction advisory council (2019-2020)**

*See* **Mental Health and Addiction Advisory Council (2019-2020)**

**Addiction and mental health services**

Recovery-oriented system of care ... *Everington* ESS15; *Romanow* ESS20; *Sigurdson, L.* ESS20

**Addiction maintenance programs**

*See* **Safe supply**

**Addiction treatment**

[*See also* **Opioid use**]

Buprenorphine treatment ... *Lembke* ESS70-72;

*Madras* ESS41; *Milliken* ESS71-72; *Yao* ESS71

Council of Chief Medical Officers of Health discussions ... *Hinshaw* ESS23-24; *Irwin* ESS23

Economic modelling ... *Shirt* ESS115

Funding, 2019-2020 ... *Romanow* ESS13

Gap medication coverage program ... *Day* ESS103; *Milliken* ESS103

Methadone treatment ... *Amery* ESS34-35, 80; *Best* ESS49-51; *Day* ESS103; *Durnin* ESS80; *Lembke* ESS70-72; *Melamed* ESS81-83; *Milliken* ESS71-72, 81-82, 94, 103; *Rosin* ESS33; *Somers* ESS31, 33, 35; *Tanguay* ESS92, 94; *Yao* ESS50, 71, 82

Naltrexone treatment availability ... *Day* ESS103; *Milliken* ESS103

Opioid agonist therapy ... *Day* ESS102-3; *Everington* ESS14; *Frey* ESS63; *Ghosh* ESS108-9; *Hinshaw* ESS12-13; *Lembke* ESS70; *Milliken* ESS54-55, 94, 103; *Rieb* ESS53-55; *Shellenberger* ESS63; *Tanguay* ESS94; *Thiessen* ESS84

Other jurisdictions, British Columbia ... *Amery* ESS34-35; *Durnin* ESS79; *Mathew* ESS37; *Somers* ESS35; *Yao* ESS79

Other jurisdictions, Portugal ... *Amery* ESS34-35; *Somers* ESS35

Programs and services ... *Hinshaw* ESS20; *Yao* ESS19-20

Recovery-oriented housing (harm reduction housing) ... *Milliken* ESS86-87; *Sigurdson, R.J.* ESS86-87; *Somers* ESS31-32; *Thiessen* ESS84, 87

Recovery-oriented system of care ... *Amery* ESS52, 80; *Best* ESS48-52; *Devine* ESS66-67; *Durnin* ESS77-80; *Frey* ESS51, 63; *Humphreys* ESS73; *Lembke* ESS70-71; *McFee* ESS101; *Milliken* ESS55, 79-80, 86; *Rieb* ESS55; *Rosin* ESS67; *Shellenberger* ESS62-63; *Shirt* ESS112-13; *Stephan* ESS51, 101; *Thiessen* ESS85-86; *Yao* ESS50, 71, 79

Relapse, risk of overdose or poisoning ... *Ganley* ESS22-23; *Hinshaw* ESS23

Scientific research ... *Ghosh* ESS110; *Lembke* ESS71-72; *Mathew* ESS39; *Milliken* ESS71-72; *Somers* ESS35-36; *Yao* ESS36, 39, 71, 110

Services for Aboriginal persons ... *Amery* ESS85; *Milliken* ESS85, 106; *Standingontheroad* ESS105-6; *Thiessen* ESS85

**Addiction treatment (continued)**

Services in correctional facilities ... *Thiessen* ESS84

Services on reserves ... *Milliken* ESS106-7; *Standingontheroad* ESS106-7; *Turton* ESS107; *Yao* ESS107

Spaces ... *Romanow* ESS20; *Sigurdson, L.* ESS20

Sublocade (continuous release buprenorphine) treatment ... *Amery* ESS101, 104; *Day* ESS103-4; *McFee* ESS100-101; *Milliken* ESS99, 103

Suboxone (buprenorphine and naloxone) treatment ... *Amery* ESS80, 101; *Day* ESS103; *Durnin* ESS80; *Lembke* ESS72; *McFee* ESS100-101; *Melamed* ESS81-83; *Milliken* ESS71-72, 81-82, 99, 103; *Yao* ESS82

Treatment addressing social/psychological determinants ... *Milliken* ESS34; *Somers* ESS34

Virtual overdose response system *See* **Digital overdose response system (DORS)**

Wraparound services ... *Amery* ESS96, 111; *Ghosh* ESS111-12; *Koivu* ESS58-59; *Melamed* ESS81; *Milliken* ESS58; *Shirt* ESS113-15; *Somers* ESS31-35; *Stephan* ESS35; *Tanguay* ESS96; *Yao* ESS33, 59, 114

**Alberta Medical Association**

Mandate ... *Ghosh* ESS110; *Warren* ESS109-10; *Yao* ESS109-10

Presentation on safe supply ... *Amery* ESS111; *Ghosh* ESS108-12; *Milliken* ESS112; *Mogus* ESS108-10, 112; *Rosin* ESS110; *Warren* ESS108-10; *Yao* ESS109-10

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

**Alcohol abuse treatment**

*See* **Addiction treatment**

**AMA**

*See* **Alberta Medical Association**

**Best, Dr. David (Participant, Safe Supply Review)**

Education and professional experience ... *Amery* ESS52; *Best* ESS48-49; *Milliken* ESS49

Presentation on safe supply ... *Best* ESS48-52; *Frey* ESS51; *Milliken* ESS49-50; *Stephan* ESS51; *Yao* ESS50-51

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

**British Columbia**

Safe supply policy and practice *See* **Safe supply: Other jurisdictions, British Columbia**

**Cannabis**

Legalization ... *Frey* ESS41-42; *Madras* ESS42; *Rosin* ESS46; *Sabet* ESS46

**Carfentanyl use**

*See* **Opioid use**

**Centre for Applied Research in Mental Health & Addiction (CARMHA)**

*See* **Safe supply: Literature review commissioned by Health ministry**

**Chief medical officer of health**

Technical briefing on safe supply *See* **Safe supply review, public/stakeholder oral presentations: Technical briefing by Health ministry**

**Chronic pain management**

Opioid use *See* **Drugs, prescription: Opioid prescription for pain**

**Committee clerk**

General remarks ... *Robert* ESS2

**Committee to Examine Safe Supply, Select Special**

COVID-19 related safety procedures ... *Chair* ESS1; *Sigurdson, L.* ESS5; *Stephan* ESS5

Establishment (Government Motion 115: carried) ... *Chair* ESS1

LAO support services ... *Chair* ESS2; *Irwin* ESS2; *Robert* ESS2

**Mandate *See* Safe supply review: Committee mandate**

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths, motion on (L. Sigurdson: carried as amended) ... *Allard* ESS6-7; *Chair* ESS6-7; *Ganley* ESS6-7; *Shepherd* ESS7-8; *Sigurdson, L.* ESS6; *Stephan* ESS6-7

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths, motion on (L. Sigurdson: carried as amended), amendment to change wording to reflection “on the lives lost due to the illness of addiction,” motion on (Allard: carried as amended) ... *Allard* ESS6-7; *Chair* ESS6-7; *Ganley* ESS6-7; *Shepherd* ESS7-8; *Stephan* ESS6-7

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths, motion on (L. Sigurdson: carried as amended), amendment to change wording to reflection “on the lives lost due to the illness of addiction,” motion on (Allard: carried as amended), request to withdraw motion (unanimous consent denied) ... *Allard* ESS6; *Chair* ESS6-7; *Ganley* ESS6-7; *Shepherd* ESS7

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths, motion on (L. Sigurdson: carried as amended), amendment to change wording to reflection “on the lives lost due to the illness of addiction,” motion on (Allard: carried as amended), subamendment to change wording to “to commemorate the lives lost in Alberta due to drug poisoning, overdoses, and lives lost due to the illness of addiction,” motion on (Shepherd: carried) ... *Allard* ESS7; *Shepherd* ESS7-8; *Stephan* ESS7

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths, motion on (L. Sigurdson: carried as amended), amendment to change wording to reflection “on the lives lost due to the illness of addiction,” motion on (Allard: carried as amended), subamendment to change “the illness of addiction” to “drug addiction,” motion on (Stephan: ruled out of order) ... *Chair* ESS6; *Stephan* ESS6

Procedure ... *Chair* ESS1-2

Procedure, speaking time ... *Chair* ESS15-16; *Sigurdson, L.* ESS15-16

Remarks in Cree ... *Shirt* ESS114

Subcommittee on committee business appointment, motion on (Allard: carried) ... *Allard* ESS3-4; *Ganley* ESS4-5

Subcommittee on committee business appointment, motion on (Allard: carried), amendment to add that quorum must include at least one opposition member, motion on (Ganley: defeated) ... *Ganley* ESS4; *Milliken* ESS4; *Shepherd* ESS4-5; *Sigurdson, L.* ESS4-5; *Stephan* ESS5; *Yao* ESS4

**Committee to Examine Safe Supply, Select Special (continued)**

Subcommittee on committee business reports ... *Chair* ESS24; *Milliken* ESS24

Teleconferencing and videoconferencing ... *Chair* ESS5; *Sigurdson, L.* ESS5

Teleconferencing and videoconferencing permitted for duration of committee’s mandate, motion on (Shepherd: carried unanimously) ... *Chair* ESS1; *Shepherd* ESS1

**Communications planning**

No-cost, low-cost, and paid options ... *Laurie* ESS26

No-cost or low-cost plan to be prepared by communications services, motion on (Yao: carried) ... *Yao* ESS26

**Communications services (LAO)**

General remarks ... *Robert* ESS2

**Correctional facilities**

Addiction treatment services *See* **Addiction treatment: Services in correctional facilities**

**Crime**

Relation to drug use [*See also* **Opioids: Diversion from medical use**]; *Amery* ESS100; *Durnin* ESS78-79; *Koivu* ESS58; *McFee* ESS97-98, 100-101; *Milliken* ESS100; *Rosin* ESS33; *Somers* ESS30-31, 33; *Stephan* ESS78, 101

Relation to drug use, scientific research ... *Best* ESS49

**Crystal meth (drug)**

*See* **Methamphetamine use**

**Day, Dr. Nathaniel (Participant, Safe Supply Review)**

Education and professional experience ... *Day* ESS102

Presentation on safe supply ... *Amery* ESS104; *Day* ESS101-5; *Milliken* ESS103-5; *Stephan* ESS103

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

**Devine, Dr. Jeremy (Participant, Safe Supply Review)**

Education and professional experience ... *Devine* ESS65; *Rosin* ESS67

Presentation on safe supply ... *Amery* ESS68; *Devine* ESS65-69; *Frey* ESS67; *Milliken* ESS68-69; *Rosin* ESS67; *Stephan* ESS69

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

**Digital overdose response system (DORS)**

General remarks ... *Everington* ESS15; *Stephan* ESS87; *Thiessen* ESS87

**Dodd, Zoë**

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings**

**Dong, Dr. Kathryn**

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

**DORS**

*See* **Digital overdose response system (DORS)**

**Drugs, illicit**

Decriminalization of personal-possession offences ... *Milliken* ESS85; *Thiessen* ESS85

Distribution and sale ... *Amery* ESS100-101; *McFee* ESS97-101; *Stephan* ESS99

**Drugs, illicit (continued)**

Legalization ... *Madras* ESS43-44; *Milliken* ESS55, 86; *Rieb* ESS55; *Rosin* ESS43, 45-46, 65; *Sabet* ESS45-46; *Shellenberger* ESS65; *Thiessen* ESS86

**Drugs, prescription**

Opioid prescription for pain ... *Amery* ESS96; *Hinshaw* ESS12, 16, 18-19; *Humphreys* ESS73; *Madras* ESS42-43; *Mathew* ESS38-39; *Milliken* ESS18-19; *Posner* ESS88-89; *Romanow* ESS15, 18; *Rosin* ESS38, 89, 95; *Tanguay* ESS92, 95-96; *Yao* ESS16, 38-39, 42

Opioid prescription for pain, scientific research ... *Sabet* ESS44-45

Opioid prescription for pain, United States ... *Tanguay* ESS93

**Durnin, Dr. Máire (Participant, Safe Supply Review)**

Education and professional experience ... *Durnin* ESS76-77

Presentation on safe supply ... *Amery* ESS80; *Durnin* ESS76-80; *Milliken* ESS78-80; *Stephan* ESS78-79; *Yao* ESS79

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Each+Every**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Emergency medical services (ambulances, etc.)**

Caseload related to opioid use, 2020-2021 ... *Hinshaw* ESS12

**England**

Safe supply policy and practice *See Safe supply: Other jurisdictions, England*

**Examine Safe Supply, Select Special Committee to**

*See Committee to Examine Safe Supply, Select Special*

**Fentanyl treatment**

*See Addiction treatment*

**Fentanyl use**

*See Opioid use*

**Fort, Amber**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings*

**Goulão, Dr. João**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings*

**Government motions (2021)**

No. 115 *See Committee to Examine Safe Supply, Select Special: Establishment (Government Motion 115: carried)*

**Hallucinogenic drugs**

Legalization ... *Madras* ESS43-44; *Rosin* ESS43

**Health ministry**

*See Ministry of Health*

**Hospital emergency services**

Caseload related to substance use, 2020-2021 ... *Hinshaw* ESS12

**Humphreys, Dr. Keith (Participant, Safe Supply Review)**

Education and professional experience ... *Humphreys* ESS72

Presentation on safe supply ... *Amery* ESS74; *Humphreys* ESS72-76; *Milliken* ESS75-76; *Rosin* ESS74; *Sigurdson, R.J.* ESS76; *Stephan* ESS75; *Yao* ESS75

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Hyshka, Dr. Elaine**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**IOAT (injectable opioid agonist therapy)**

*See Addiction treatment: Opioid agonist therapy*

**Johnson, Cheyenne**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings*

**Kahan, Dr. Meldon**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Kendall, Dr. Perry**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings*

**Koivu, Dr. Sharon (Participant, Safe Supply Review)**

Education and professional experience ... *Amery* ESS59; *Koivu* ESS57, 59

Presentation on safe supply ... *Amery* ESS59; *Koivu* ESS56-60; *Milliken* ESS57

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Lam, Dr. Vincent**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Lembke, Dr. Anna (Participant, Safe Supply Review)**

Education and professional experience ... *Lembke* ESS71; *Milliken* ESS71

Presentation on safe supply ... *Lembke* ESS69-72; *Milliken* ESS71-72; *Yao* ESS71

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**London InterCommunity Health Centre**

Safe supply report ... *Devine* ESS66; *Hinshaw* ESS23; *Irwin* ESS23; *Romanow* ESS23

Safe supply services ... *Koivu* ESS57-58

**Madras, Dr. Bertha (Participant, Safe Supply Review)**

Education and professional credentials ... *Frey* ESS42; *Madras* ESS42

Presentation on safe supply ... *Frey* ESS41-42; *Madras* ESS40-44; *Rosin* ESS43; *Yao* ESS42-43

**Madras, Dr. Bertha (Participant, Safe Supply Review)***(continued)*

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Marijuana***See Cannabis***Maslow's hierarchy of needs**

General remarks ... *Durnin* ESS79; *Koivu* ESS59-60; *Somers* ESS33-34; *Yao* ESS33, 59-60, 79

**Mathew, Dr. Nickie (Participant, Safe Supply Review)**

Presentation on safe supply ... *Amery* ESS39-40; *Chair* ESS38; *Mathew* ESS36-40; *Milliken* ESS40; *Rosin* ESS38; *Stephan* ESS40; *Yao* ESS38-39

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**McFee, Dale (Participant, Safe Supply Review)**

Presentation on safe supply ... *Amery* ESS100-101; *McFee* ESS97-101; *Milliken* ESS99; *Stephan* ESS99, 101

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Medical Association, Alberta***See Alberta Medical Association***Medication***See Drugs, prescription***Melamed, Dr. Jennifer (Participant, Safe Supply Review)**

Education and professional experience ... *Melamed* ESS80-82; *Yao* ESS82

Presentation on safe supply ... *Melamed* ESS80-84; *Milliken* ESS81-82; *Stephan* ESS83; *Yao* ESS82

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Mental Health and Addiction Advisory Council (2019-2020)**

Report ... *Romanow* ESS15-16; *Sigurdson, L.* ESS15-16

**Mental health services**

Funding, 2019-2020 ... *Romanow* ESS13

**Mental Health Services Protection Act**

Residential addiction treatment services provisions ...

*Puttick* ESS14

Supervised consumption services provisions ... *Puttick* ESS14

**Methamphetamine use**

Destigmatization ... *Frey* ESS63; *Shellenberger* ESS63-64; *Yao* ESS63

**Ministry of Health**

Officials to support committee work and attend meetings ... *Chair* ESS24

Officials to support committee work and attend meetings, motion on (Allard: carried) ... *Allard* ESS3

Technical briefing on safe supply *See Safe supply review, public/stakeholder oral presentations: Technical briefing by Health ministry*

**Moms Stop the Harm**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Motions (procedure)**

Administrative corrections to amendments and subamendments ... *Chair* ESS7-8; *Koenig* ESS8

Chief medical officer technical briefing invitation, request to introduce motion (granted) ... ESS3

Crossjurisdictional comparison, research services to prepare (Irwin: carried), amendment to specify academic journals and literature review and comparison of Canadian policies, request to introduce (not granted) ... ESS9

Literature review commissioned by Health ministry, summary, invitation to Dr. Julian Somers for presentation (Stephan: carried as amended), amendment to change "Simon Fraser University" to "Centre for Applied Research in Mental Health & Addiction," request to present amendment (granted) ... ESS28

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths (L. Sigurdson: carried as amended), amendment to change wording to reflection "on the lives lost due to the illness of addiction" (Allard: carried as amended), request to withdraw motion (unanimous consent denied) ... ESS6-7

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths (L. Sigurdson: carried as amended), amendment to change wording to reflection "on the lives lost due to the illness of addiction" (Allard: carried as amended), subamendment to change "the illness of addiction" to "drug addiction" (Stephan: ruled out of order) ... ESS6

Notice of motions and amendments ... *Chair* ESS1

Summary of literature review, request to present motion (granted) ... ESS26

**Motions (Legislative Assembly, 2021)**

No. 115 *See Committee to Examine Safe Supply, Select Special: Establishment (Government Motion 115: carried)*

**Motions (committee)**

Chief medical officer of health technical briefing, invitation (Shepherd: carried) ... ESS3

Communications plan (low-cost or no-cost options) prepared by communications services (Yao: carried) ... ESS26

Draft stakeholder list approval (Allard: carried) ... ESS24-25

Health ministry support of committee work and meeting attendance (Allard: carried) ... ESS3

Health ministry technical briefing, invitation (Allard: carried) ... ESS3

Invitations for stakeholder presentations, March 21 to 25, 2022 (Yao: carried) ... ESS115

Literature review commissioned by Health ministry, summary, invitation to Dr. Julian Somers for presentation (Stephan: carried as amended) ... ESS26-28

Literature review commissioned by Health ministry, summary, invitation to Dr. Julian Somers for presentation (Stephan: carried as amended), amendment to change "Simon Fraser University" to "Centre for Applied Research in Mental Health & Addiction" (Shepherd: carried) ... ESS28

Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths (L. Sigurdson: carried as amended) ... ESS6-8

**Motions (committee) (continued)**

- Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths (L. Sigurdson: carried as amended), amendment to change wording to reflection “on the lives lost due to the illness of addiction” (Allard: carried as amended) ... ESS6–7
- Moment of silent reflection at starts of meetings to commemorate drug poisoning and overdose deaths (L. Sigurdson: carried as amended), amendment to change wording to reflection “on the lives lost due to the illness of addiction” (Allard: carried as amended), subamendment to change wording to “to commemorate the lives lost in Alberta due to drug poisoning, overdoses, and lives lost due to the illness of addiction” (Shepherd: carried) ... ESS7–8
- Safe supply, research services to prepare crossjurisdictional comparison (Irwin: carried) ... ESS8–10
- Safe supply review, public written submissions invited (Irwin: carried) ... ESS25–26
- Subcommittee on committee business appointment (Allard: carried) ... ESS3–5
- Subcommittee on committee business appointment (Allard: carried), amendment to add that quorum must include at least one opposition member (Ganley: defeated) ... ESS4–5
- Teleconferencing and videoconferencing permitted for duration of committee’s mandate (Shepherd: carried unanimously) ... ESS1

**Netherlands**

- Safe supply policy and practice *See Safe supply: Other jurisdictions, the Netherlands*

**Norway**

- Safe supply policy and practice *See Safe supply: Other jurisdictions, Norway*

**Nova Scotia**

- Safe supply policy and practice *See Safe supply: Other jurisdictions, Nova Scotia*

**Nyx, Erys**

- Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings*

**OAT**

- See Addiction treatment: Opioid agonist therapy*

**Ontario**

- Safe supply policy and practice *See Safe supply: Other jurisdictions, Ontario*

**Opioid addiction**

- Comparison with other addiction ... *Madras* ESS41, 43; *Yao* ESS42
- Opioid agonist therapy ... *Madras* ESS41
- Statistics, comparison with other jurisdictions ... *Rosin* ESS95; *Tanguay* ESS95–96
- Transition from prescription drug use ... *Lembke* ESS72; *Mathew* ESS38–39; *Milliken* ESS72; *Rieb* ESS52, 55; *Rosin* ESS38; *Sabet* ESS44–45; *Thiessen* ESS84; *Yao* ESS38–39, 55
- Transition from prescription drug use, scientific research ... *Day* ESS101–3

**Opioid treatment**

- See Addiction treatment*

**Opioid use**

- [*See also Substance use*]
- Deaths ... *Milliken* ESS94; *Sabet* ESS45; *Tanguay* ESS92, 94

**Opioid use (continued)**

- Deaths, 2020-2021 ... *Everington* ESS13–14; *Ganley* ESS17–18; *Hinshaw* ESS12–13, 17–19; *Irwin* ESS19; *Stephan* ESS17
- Deaths, Aboriginal persons ... *Hinshaw* ESS13
- Deaths, medical examiner review (2017) ... *Hinshaw* ESS12
- Destigmatization ... *Amery* ESS96; *Frey* ESS63; *Posner* ESS88–90; *Shellenberger* ESS63–64; *Stephan* ESS90; *Tanguay* ESS96; *Yao* ESS63
- Harm reduction strategies ... *Ganley* ESS23; *Hinshaw* ESS19–20, 23; *Irwin* ESS19; *Romanow* ESS23; *Yao* ESS19–20
- Naloxone kit availability ... *Hinshaw* ESS12–13
- Overdose impacts, 1990 to present ... *Hinshaw* ESS16; *Yao* ESS16
- Overdoses ... *Durnin* ESS77; *Lembke* ESS70; *Milliken* ESS56; *Posner* ESS88; *Rieb* ESS56; *Sabir* ESS46; *Stephan* ESS46
- Overdoses, research studies ... *Madras* ESS43; *Rosin* ESS43; *Sabet* ESS44
- Overdoses, statistics ... *Durnin* ESS79; *Ghosh* ESS108; *Humphreys* ESS75; *Mathew* ESS37–38; *Rosin* ESS38, 74; *Shirt* ESS112; *Thiessen* ESS84; *Yao* ESS79
- Prescription drug use *See Drugs, prescription*
- Statistics, comparison with other jurisdictions ... *Everington* ESS14–15
- Supervised consumption sites ... *Best* ESS49, 51–52; *Frey* ESS51, 63; *Ghosh* ESS109; *Koivu* ESS57–58; *Puttick* ESS14; *Shellenberger* ESS63; *Somers* ESS30; *Stephan* ESS51; *Tanguay* ESS93–94
- Supervised consumption sites, client provision of personal health numbers ... *Ganley* ESS17; *Romanow* ESS17–18
- Supervised consumption sites, laws and legislation *See Mental Health Services Protection Act: Supervised consumption services provisions*

**Opioids**

- Decriminalization ... *Frey* ESS41–42; *Madras* ESS42
- Diversion from medical use [*See also Drugs, illicit*]; *Best* ESS48–50; *Day* ESS103; *Durnin* ESS77–78; *Humphreys* ESS74; *Koivu* ESS57–58; *Mathew* ESS37–38, 40; *Melamed* ESS81; *Milliken* ESS49, 78; *Mogus* ESS108–9; *Posner* ESS90–91; *Rieb* ESS53; *Rosin* ESS74; *Somers* ESS32; *Stephan* ESS40, 90, 103; *Tanguay* ESS93; *Thiessen* ESS84

**Organized crime**

- Drug involvement *See Drugs, illicit: Distribution and sale*

**OOD (opioid use disorder)**

- See Opioid addiction; Opioid use*

**Parliamentary Counsel**

- General remarks ... *Robert* ESS2

**Pharmaceutical manufacturers**

- Development and marketing of opioids ... *Amery* ESS47; *Humphreys* ESS73; *Madras* ESS42–43; *Mathew* ESS36–37; *Posner* ESS88–89, 91; *Rieb* ESS52; *Rosin* ESS46, 89; *Sabet* ESS44, 46–47; *Tanguay* ESS92–93; *Yao* ESS42, 91

**Pharmaceuticals**

- See Drugs, prescription*

**Physician education**

- Education on addiction issues ... *Mathew* ESS39; *Yao* ESS39
- Opioid prescription ... *Hinshaw* ESS16; *Yao* ESS16

**Portugal**

Safe supply policy and practice *See Safe supply: Other jurisdictions, Portugal*

**Posner, Gerald (Participant, Safe Supply Review)**

Education and professional experience ... *Milliken* ESS90; *Posner* ESS87–88

Presentation on safe supply ... *Milliken* ESS90; *Posner* ESS87–91; *Rosin* ESS89; *Stephan* ESS90; *Yao* ESS91

**Prescription drugs**

*See Drugs, prescription*

**Ranger, Corey**

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings*

**Research services (LAO)**

General remarks ... *Irwin* ESS2; *Robert* ESS2

**Resolutions, debatable**

*See Motions (committee)*

**Rieb, Dr. Launette (Participant, Safe Supply Review)**

Education and professional experience ... *Rieb* ESS52, 54–55; *Yao* ESS55

Presentation on safe supply ... *Milliken* ESS54–56; *Rieb* ESS52–57; *Rosin* ESS56; *Yao* ESS55–56

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**ROSC**

*See Addiction and mental health services: Recovery-oriented system of care*

**Sabet, Dr. Kevin (Participant, Safe Supply Review)**

Education and professional experience ... *Amery* ESS47; *Sabet* ESS44

Presentation on safe supply ... *Amery* ESS47; *Milliken* ESS48; *Rosin* ESS45–46; *Sabet* ESS44–48; *Stephan* ESS46–47; *Yao* ESS45

Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Saddle Lake Cree Nation**

General remarks ... *Shirt* ESS113; *Yao* ESS113

**Safe supply**

Crossjurisdictional comparison, research services to prepare, motion on (Irwin: carried) ... *Allard* ESS10; *Chair* ESS9; *Frey* ESS9–10; *Ganley* ESS9–10; *Irwin* ESS8; *Koenig* ESS10; *Robert* ESS8–10; *Shepherd* ESS8–10; *Yao* ESS9

Crossjurisdictional comparison, research services to prepare, motion on (Irwin: carried), amendment to specify academic journals and literature review and comparison of Canadian policies, request to introduce (not granted) ... *Chair* ESS9; *Robert* ESS9; *Sigurdson, L.* ESS9; *Stephan* ESS9

Definition ... *Amery* ESS68, 104; *Day* ESS104; *Devine* ESS66, 68; *Hinshaw* ESS21; *Humphreys* ESS75; *Lembke* ESS71; *Mogus* ESS109; *Romanow* ESS15, 21; *Sabet* ESS44, 46–47; *Shellenberger* ESS61–62; *Somers* ESS29–30; *Stephan* ESS20–21, 46–47; *Yao* ESS71, 75

Economic modelling ... *Humphreys* ESS75; *Posner* ESS88; *Shirt* ESS115; *Stephan* ESS75

Ethical and philosophical issues ... *Devine* ESS67–68; *Frey* ESS67; *Humphreys* ESS76; *Lembke* ESS69–70; *Sigurdson, R.J.* ESS76

**Safe supply (continued)**

Federal pilot program ... *Devine* ESS65; *Milliken* ESS18; *Romanow* ESS18, 22; *Shepherd* ESS21–22  
 General remarks ... *Amery* ESS52; *Best* ESS51–52; *Day* ESS103–5; *Devine* ESS69; *Frey* ESS51; *McFee* ESS98–99; *Milliken* ESS69, 103–5, 114; *Posner* ESS89; *Rieb* ESS55–56; *Rosin* ESS56, 89; *Shirt* ESS112–14; *Sigurdson, R.J.* ESS85; *Stephan* ESS51, 87; *Thiessen* ESS84–85, 87; *Yao* ESS55, 113

Health ministry use of external expertise ... *Hinshaw* ESS21; *Puttick* ESS14; *Romanow* ESS11–12, 21; *Shepherd* ESS21

Individuals accessing, employment ... *Rosin* ESS33; *Somers* ESS33

Literature review commissioned by Health ministry ... *Chair* ESS16, 25; *Irwin* ESS23; *Puttick* ESS14–15; *Romanow* ESS17, 23; *Shepherd* ESS16–17; *Yao* ESS16, 25

Literature review commissioned by Health ministry, summary, invitation to Dr. Julian Somers for presentation, motion on (Stephan: carried as amended) ... *Chair* ESS28; *Ganley* ESS27; *Robert* ESS27; *Shepherd* ESS26, 28; *Stephan* ESS26–28

Literature review commissioned by Health ministry, summary, invitation to Dr. Julian Somers for presentation, motion on (Stephan: carried as amended), amendment to change “Simon Fraser University” to “Centre for Applied Research in Mental Health & Addiction,” motion on (Shepherd: carried) ... *Shepherd* ESS28; *Stephan* ESS28

Literature review commissioned by Health ministry, summary, invitation to Dr. Julian Somers for presentation, motion on (Stephan: carried as amended), amendment to change “Simon Fraser University” to “Centre for Applied Research in Mental Health & Addiction,” request to present amendment (granted) ... *Shepherd* ESS28

Literature review commissioned by Health ministry, summary, request to present motion (granted) ... *Chair* ESS26; *Shepherd* ESS26; *Stephan* ESS26

Other jurisdictions ... *Devine* ESS67; *Humphreys* ESS76; *Lembke* ESS69–70; *Milliken* ESS76; *Mogus* ESS110; *Rosin* ESS67, 110

Other jurisdictions, British Columbia ... *Amery* ESS22, 39, 80, 101, 111; *Day* ESS105; *Devine* ESS65–66, 68–69; *Durnin* ESS77–80; *Ghosh* ESS111; *Mathew* ESS39–40; *McFee* ESS97–101; *Melamed* ESS82–84; *Milliken* ESS18, 68–69, 78–79, 82–83, 99, 105; *Mogus* ESS108–9; *Rieb* ESS53–54; *Romanow* ESS15, 18, 22; *Rosin* ESS46; *Somers* ESS30–32, 46; *Stephan* ESS40, 78–79, 83, 99; *Yao* ESS63, 83

Other jurisdictions, England ... *Amery* ESS68; *Best* ESS49–50; *Devine* ESS68; *Milliken* ESS49

Other jurisdictions, Norway ... *Shellenberger* ESS62

Other jurisdictions, Nova Scotia ... *Romanow* ESS15

Other jurisdictions, Ontario [*See also London*

**InterCommunity Health Centre**]; *Amery* ESS80; *Durnin* ESS80; *Ghosh* ESS109; *Koivu* ESS57–58; *Romanow* ESS15; *Rosin* ESS33; *Somers* ESS33

Other jurisdictions, Portugal ... *Devine* ESS66; *Durnin* ESS79; *McFee* ESS99; *Milliken* ESS55; *Rieb* ESS55; *Shellenberger* ESS62, 64; *Somers* ESS31; *Stephan* ESS79; *Tanguay* ESS93; *Yao* ESS63

Other jurisdictions, Scotland ... *Best* ESS48–49; *Somers* ESS35; *Stephan* ESS35

Other jurisdictions, Switzerland ... *Day* ESS103; *Milliken* ESS103; *Posner* ESS91; *Stephan* ESS90



**Safe supply (continued)**

- Other jurisdictions, the Netherlands ... *Frey* ESS63; *Posner* ESS90–91; *Shellenberger* ESS61–63; *Stephan* ESS90
- Other jurisdictions, United States ... *Humphreys* ESS75; *Milliken* ESS75; *Posner* ESS88, 91; *Shellenberger* ESS61, 64–65; *Stephan* ESS64, 90
- Pilot program, AMA recommendation ... *Amery* ESS111; *Ghosh* ESS109–11; *Mogus* ESS110; *Rosin* ESS110; *Yao* ESS110
- Prescribed and nonprescribed models ... *Ghosh* ESS108
- Scientific research ... *Amery* ESS39, 59, 74, 111; *Best* ESS50–51; *Day* ESS103–4; *Devine* ESS65–66; *Ghosh* ESS109, 112; *Humphreys* ESS73–76; *Koivu* ESS59–60; *Lembke* ESS70, 72; *Madras* ESS40–43; *Mathew* ESS37–40; *Milliken* ESS34, 40, 48, 50, 54, 56, 71–72, 75–76, 112; *Mogus* ESS112; *Posner* ESS87–88, 90; *Rieb* ESS52–54, 56–57; *Rosin* ESS38, 65, 74, 89; *Sabet* ESS44–45, 48; *Shellenberger* ESS62, 65; *Somers* ESS32, 34–36; *Stephan* ESS35–36, 40, 103; *Yao* ESS36, 42, 45, 51
- Technical briefing by Health ministry ... *Amery* ESS22; *Everington* ESS13–14; *Ganley* ESS17–18, 22–23; *Hinshaw* ESS12–13, 16–21, 23–24; *Irwin* ESS19, 23; *Milliken* ESS18–19, 22; *Puttick* ESS14–15; *Romanow* ESS11–18, 20–23; *Shepherd* ESS16–17, 21–22; *Sigurdson, L.* ESS15–16, 20; *Stephan* ESS17, 20–21; *Yao* ESS16, 19–20
- Witnessed doses ... *Day* ESS105; *Koivu* ESS58–59; *Milliken* ESS58, 105; *Mogus* ESS108–9

**Safe Supply, Select Special Committee to Examine**  
*See Committee to Examine Safe Supply, Select Special*

**Safe supply review**

- Committee mandate ... *Chair* ESS2; *Shepherd* ESS16–17
- Scope of review ... *Milliken* ESS112; *Shellenberger* ESS62
- Timeline ... *Chair* ESS25; *Stephan* ESS25; *Yao* ESS25

**Safe supply review, public/stakeholder oral presentations**

- Invitations for February 15 to March 4, 2022, meetings, motion on (Allard: carried) ... *Allard* ESS24–25; *Chair* ESS24; *Ganley* ESS24–25; *Irwin* ESS24; *Yao* ESS25
- Invitations for March 21 to 25, 2022, meetings, motion on (Yao: carried) ... *Yao* ESS115
- Invitations for March 21 to 25, 2022, meetings, request to consider motion ... *Chair* ESS115
- Presentations, February 15 to 17, 2022 ... *Amery* ESS34–35, 39–40, 47, 59, 68, 74, 80, 85, 96, 100–101, 104, 106–7, 111; *Best* ESS48–52; *Chair* ESS36, 38; *Day* ESS101–5; *Devine* ESS65–69; *Durnin* ESS76–80; *Frey* ESS41–42, 51, 63, 67; *Ghosh* ESS108–12; *Humphreys* ESS72–76; *Koivu* ESS56–60; *Lembke* ESS69–72; *Madras* ESS40–44; *Mathew* ESS36–40; *McFee* ESS97–101; *Melamed* ESS80–84; *Milliken* ESS34, 36, 40, 48–50, 54–57, 68–69, 71–72, 75–76, 78–82, 86–87, 90, 94, 99, 103–5, 112, 114; *Mogus* ESS108–10, 112; *Posner* ESS87–91; *Rieb* ESS52–57; *Rosin* ESS33, 38, 43, 45–46, 56, 65, 67, 74, 89, 95, 110; *Sabet* ESS44–48; *Shellenberger* ESS61–65; *Shirt* ESS112–15; *Sigurdson, R.J.* ESS76, 86–87; *Somers* ESS29–36; *Standingontheroad* ESS105–8; *Stephan* ESS35–36, 40, 46–47, 51, 64–65, 69, 75, 78–79, 83, 87, 90, 99, 101, 103; *Tanguay* ESS91–96; *Thiessen* ESS84–87; *Turton* ESS107; *Warren* ESS108–10; *Yao* ESS33, 36, 38–39, 42–43, 45, 50–51, 55–56, 63–64, 71, 75, 79, 82, 91, 107, 109–10, 113–14

**Safe supply review, public/stakeholder oral presentations (continued)**

- Technical briefing by chief medical officer of health, invitation, motion on (Shepherd: carried) ... *Chair* ESS3; *Shepherd* ESS3
- Technical briefing by chief medical officer of health, invitation, request to introduce motion (granted) ... *Allard* ESS3; *Chair* ESS3; *Robert* ESS3; *Shepherd* ESS3
- Technical briefing by Health ministry, invitation, motion on (Allard: carried) ... *Allard* ESS3

**Safe supply review, public/stakeholder written submissions**

- Invitations ... *Chair* ESS5, 25; *Sigurdson, L.* ESS5
- Invitations for public submissions, motion on (Irwin: carried) ... *Irwin* ESS25–26; *Milliken* ESS26

**Salvalaggio, Dr. Ginetta**

- Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Scotland**

- Safe supply policy and practice *See Safe supply: Other jurisdictions, Scotland*

**SCSs**

- See Opioid use: Supervised consumption sites*

**Select Special Committee to Examine Safe Supply**  
*See Committee to Examine Safe Supply, Select Special*

**Shellenberger, Michael (Participant, Safe Supply Review)**

- Education and professional experience ... *Shellenberger* ESS61
- Presentation on safe supply ... *Frey* ESS63; *Rosin* ESS65; *Shellenberger* ESS61–65; *Stephan* ESS64–65; *Yao* ESS63–64
- Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Shirt, Chief Eric (Participant, Safe Supply Review)**

- Presentation on safe supply ... *Milliken* ESS114; *Shirt* ESS112–15; *Yao* ESS113–14
- Presentation on safe supply, invitation *See Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings*

**Social services**

- Services on reserves, federal funding ... *Standingontheroad* ESS107–8; *Yao* ESS107

**Somers, Dr. Julian (Participant, Safe Supply Review)**

- Commissioned literature review *See Safe supply: Literature review commissioned by Health ministry*
- Presentation on safe supply literature review ... *Amery* ESS34–35; *Chair* ESS36; *Milliken* ESS34, 36; *Rosin* ESS33; *Somers* ESS29–36; *Stephan* ESS35–36; *Yao* ESS33, 36

**Standing Orders of the Legislative Assembly of Alberta**  
 SO 52.041, notice of amendments *See Motions (procedure): Notice of motions and amendments*

**Standingontheroad, Chief Leonard (Participant, Safe Supply Review)**

- Personal and professional experience ... *Amery* ESS106; *Standingontheroad* ESS105–6

**Standingontheroad, Chief Leonard (Participant, Safe Supply Review) (continued)**

Presentation on safe supply ... *Amery* ESS106–7; *Standingontheroad* ESS105–8; *Turton* ESS107; *Yao* ESS107

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

**Stanford-Lancet Commission on the North American Opioid Crisis**

Recommendations ... *Amery* ESS74; *Humphreys* ESS72–76; *Milliken* ESS74, 76; *Rosin* ESS74; *Sigurdson, R.J.* ESS76

Recommendations on opioid prescription to addicts ... *Rosin* ESS33; *Somers* ESS32–33

**Sublocade**

*See* **Addiction treatment: Opioid agonist therapy**

**Substance abuse and addiction**

Harm reduction strategies, DORS *See* **Digital overdose response system (DORS)**

Treatment *See* **Addiction treatment**

**Substance use**

[*See also* **Opioid use**]

Harm reduction ... *Amery* ESS104; *Day* ESS104; *Devine* ESS69; *Humphreys* ESS74; *Milliken* ESS90; *Posner* ESS90; *Rosin* ESS74; *Shellenberger* ESS61–62; *Sigurdson, R.J.* ESS86–87; *Somers* ESS30; *Stephan* ESS69; *Thiessen* ESS86–87

Harm reduction, safe supply *See* **Safe supply**

Hospitalizations, 2020-2021 ... *Hinshaw* ESS12

Overdoses ... *Amery* ESS34; *Somers* ESS34

Overdoses, relation to unemployment ... *Rosin* ESS33; *Somers* ESS31–33

Prevention ... *Humphreys* ESS75; *Milliken* ESS75

**Suicide**

Determination by medical examiner's office ... *Hinshaw* ESS17; *Romanow* ESS17; *Stephan* ESS17

Safe supply policy and practice *See* **Safe supply: Other jurisdictions, Switzerland**

**Tanguay, Dr. Robert (Participant, Safe Supply Review)**

Education and professional experience ... *Tanguay* ESS92

Presentation on safe supply ... *Amery* ESS96; *Milliken* ESS94; *Rosin* ESS95; *Tanguay* ESS91–96

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

**Thiessen, Earl (Participant, Safe Supply Review)**

Personal and professional experience ... *Milliken* ESS87; *Sigurdson, R.J.* ESS85; *Thiessen* ESS84, 86–87

Presentation on safe supply ... *Amery* ESS85; *Milliken* ESS86–87; *Sigurdson, R.J.* ESS86–87; *Stephan* ESS87; *Thiessen* ESS84–87

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for February 15 to March 4, 2022, meetings**

Presentation on safe supply, video ... *Amery* ESS85; *Thiessen* ESS84

**Tyndall, Dr. Mark**

Presentation on safe supply, invitation *See* **Safe supply review, public/stakeholder oral presentations: Invitations for March 21 to 25, 2022, meetings**

**United States**

Safe supply policy and practice *See* **Safe supply: Other jurisdictions, United States**

**Virtual opioid dependency program**

General remarks ... *Day* ESS102–4; *Milliken* ESS103; *Stephan* ESS103

Program expansion ... *Everington* ESS14

**VODP**

*See* **Virtual opioid dependency program**